“Genetic Polymorphism in CYP2D6 and its Association with the Safety and Efficacy of Fluvoxamine in Patients with Major Depressive Disorder ” (2023) Precision Medicine Communications, 3(1), pp. 43–49. doi:10.55627/pmc.003.01.0301.